These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9422478)

  • 1. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
    Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
    Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC).
    Bredeson C; Malcolm J; Davis M; Bence-Bruckler I; Kearns B; Huebsch L
    Bone Marrow Transplant; 1997 Nov; 20(10):889-96. PubMed ID: 9404932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study.
    Limat S; Woronoff-Lemsi MC; Deconinck E; Racadot E; Jacquet M; Herve P; Cahn JY
    Bone Marrow Transplant; 2000 May; 25(9):997-1002. PubMed ID: 10800070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
    Vicent MG; Madero L; Chamorro L; Madero R; Diaz MA
    Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic costs of autotransplantation of hematopoietic progenitors].
    de Arriba F; Heras I; del Carmen Garcia M; Moraleda JM; Funes C; Ferrer F; Vicente V
    Med Clin (Barc); 1996 Mar; 106(9):329-32. PubMed ID: 8667698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
    Bennett C; Waters T; Stinson T; Almagor O; Pavletic Z; Tarantolo S; Bishop M
    Bone Marrow Transplant; 1999 Sep; 24(5):555-60. PubMed ID: 10482942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Difference in costs of autologous transplantation of peripheral and bone marrow hematopoietic stem cells. A retrospective analysis over 1 year of transplantation in lymphoma, Hodgkin's disease and myeloma in a Center].
    Rio B; Marjanovic Z; Belhocine R; Vekhoff A; Andrieu V; Klaren J; Boccaccio C; Delmer A; Ajchenbaum-Cymbalista F; Hunault M; Bazarbachi A; Lévy V; Andreu G; Zittoun R
    Ann Med Interne (Paris); 1996; 147(5):313-9. PubMed ID: 9033732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
    Messori A; Bonistalli L; Costantini M; Alterini R
    Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
    Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.
    Sinitsyn Y; Malone A; Mandeli J; Grosskreutz C; Osman K; Scigliano E; Shi P; Isola L
    Cytotherapy; 2009; 11(4):457-63. PubMed ID: 19499401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital.
    Mazza P; Secondo E; Palazzo G; Amurri B; Manna N; Miloro G; Moscogiuri R
    Haematologica; 1999 Feb; 84(2):142-9. PubMed ID: 10091413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer.
    De Rosa L; Lalle M; Pandolfi A; Pescador L
    Bone Marrow Transplant; 2001 May; 27(10):1031-5. PubMed ID: 11438817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
    van Agthoven M; Kramer MH; Sonneveld P; van der Hem KG; Huijgens PC; Wijermans PW; Kluin-Nelemans HC; Schaafsma MR; Biesma DH; Mattijssen V; Uyl-de Groot CA; Hagenbeek A
    Haematologica; 2005 Oct; 90(10):1422-32. PubMed ID: 16219580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F; Cavenaghi L; de Melo CM
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Economic study of the cost of peripheral blood hematopoietic precursor autotransplantation compared with bone marrow transplantation].
    Juliá A; Bueno J; Gadea N; Massuet L; del Baño C
    Med Clin (Barc); 1995 Jun; 105(4):131-5. PubMed ID: 7623504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.